Analysis of Circulating Tumor Markers in Blood

Last updated: March 27, 2025
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neurofibromatosis

Colorectal Cancer

Cancer/tumors

Treatment

Blood sampling C3

Blood sampling C12

Blood sampling C5

Clinical Study ID

NCT04025541
PROICM 2017-05 BAL
  • Ages > 18
  • All Genders

Study Summary

The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever isthe location or the stage,

  2. Man or woman ≥ 18 years,

  3. Obtaining of the informed consent signed before any procedure of specificpreselection on approval.

Exclusion

Exclusion Criteria:

  1. Private persons of freedom or under guardianship,

  2. Patient whose regular follow-up is impossible for psychological, family, social orgeographical reasons,

  3. Pregnant woman and/or breast-feeding,

  4. Unaffiliated patient to Social Protection System,

Study Design

Total Participants: 992
Treatment Group(s): 9
Primary Treatment: Blood sampling C3
Phase:
Study Start date:
May 29, 2018
Estimated Completion Date:
May 29, 2029

Study Description

The new major challenge in the research concerns the circulating biomarkers, which aim at replacing the molecular analyses on tumour tissue obtained by biopsy (for example the search for somatic mutations of cancer) by a simple blood test (liquid biopsy). The other current important challenge is to have an idea of the interest to analyse the kinetics of blood markers, in particular in answer to a clinical "event", either through the chemotherapy, a biopsy and / or surgery. There is almost no data in the literature on this aspect. It is very likely that the liberation in the blood of the blood tumoral markers is strongly dependent on medical interventions on the tumour.

The study ALCINA 2 rests exactly on the principle of small cohorts, which correspond each to a clinical situation and/or a technique of different implemented detection, so as to generate data of feasibility and proof of concept. In case of success, statistical hypotheses will be necessary for the implementation of wider studies (being then the object of a specific approval by competent authorities).

Connect with a study center

  • Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle

    Montpellier, 34298
    France

    Active - Recruiting

  • ICM

    Montpellier, 34298
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.